Coldstream Capital Management Inc. Trims Stake in Eli Lilly and Company (NYSE:LLY)

Coldstream Capital Management Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 23,732 shares of the company’s stock after selling 38 shares during the period. Eli Lilly and Company makes up about 0.5% of Coldstream Capital Management Inc.’s investment portfolio, making the stock its 26th largest position. Coldstream Capital Management Inc.’s holdings in Eli Lilly and Company were worth $21,486,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Independent Advisor Alliance lifted its stake in Eli Lilly and Company by 1.7% during the fourth quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock worth $18,810,000 after purchasing an additional 544 shares during the last quarter. Apexium Financial LP lifted its stake in Eli Lilly and Company by 1,819.1% during the fourth quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock worth $6,667,000 after purchasing an additional 10,842 shares during the last quarter. Capital Planning LLC bought a new stake in Eli Lilly and Company during the first quarter worth about $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in Eli Lilly and Company during the first quarter worth about $6,916,000. Finally, M&G Plc bought a new stake in Eli Lilly and Company during the first quarter worth about $8,896,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have sold 661,900 shares of company stock worth $604,721,602. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.0 %

LLY opened at $908.34 on Tuesday. The business has a 50 day simple moving average of $895.85 and a two-hundred day simple moving average of $829.55. The firm has a market capitalization of $863.31 billion, a price-to-earnings ratio of 133.78, a PEG ratio of 2.73 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Analysts predict that Eli Lilly and Company will post 16.51 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Analyst Upgrades and Downgrades

LLY has been the subject of several research analyst reports. Barclays lifted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Deutsche Bank Aktiengesellschaft raised Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their target price for the company from $725.00 to $1,025.00 in a research note on Monday, August 12th. Argus boosted their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Finally, Truist Financial reissued a “buy” rating and issued a $1,000.00 target price (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $961.76.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.